Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Targeting Igβ in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05312476Phase 2Withdrawn
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse events profile at 28 days. Planned start May 2026; status: withdrawn.
02
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05312476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312476.